Investment
Advanced Therapies for liver diseases
Starting a Serie A to develop a drug for NASH to start the preclinical development phase
Author
CEO at Servatrix
Madrid, Spain
SME/Start-up
servatrix.euMadrid, SpainSpin off of UAM. We are a company which develop small molecules for chronic liver diseases. MASH/NASH
Artificial Intelligence & Machine Learning
Big Data & Advanced computing
CEO
Servatrix
Investment
Advanced Therapies for liver diseases
Starting a Serie A to develop a drug for NASH to start the preclinical development phase
CEO at Servatrix
Madrid, Spain